Xenetic Biosciences, Inc. (XBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Xenetic Biosciences, Inc. (XBIO) closed at USD 2.10 on 2026-10-14, a change of -41.3 % over the past year, with a market capitalization of USD 4.71M.

Xenetic Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Xenetic Biosciences, Inc. key figures

Previous close

USD 2.10 (2026-10-14)

1-year change

-41.3 %

Market cap

USD 4.71M

Enterprise value

USD -1.76M

P/E ratio (trailing)

-1.76

P/E ratio (forward)

-3.05

EPS (trailing)

-1.14

EPS (forward)

-0.66

PEG ratio

n/a

Price to book

0.78

Revenue growth

12 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.08

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Xenetic Biosciences, Inc. and compare it with other stocks.